AU Patent

AU2019200982B2 — Opioid formulations

Assigned to Camurus AB · Expires 2019-07-18 · 7y expired

What this patent protects

Editorial Note Please Note the Abstract starts at page 54. The Claims finish at page 51. The parent has the same description and numbering but the Claim in the Divisional is shorter by 2 pages from the Parent and the abstract is numbered the same as in the Parent. - 54 Opioid Dep…

USPTO Abstract

Editorial Note Please Note the Abstract starts at page 54. The Claims finish at page 51. The parent has the same description and numbering but the Claim in the Divisional is shorter by 2 pages from the Parent and the abstract is numbered the same as in the Parent. - 54 Opioid Depot Formulations 5 A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. 10 Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019200982B2
Jurisdiction
AU
Classification
—
Expires
2019-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Camurus AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.